Discovery - University of Dundee - Online Publications

Library & Learning Centre

Filaggrin in atopic dermatitis

Filaggrin in atopic dermatitis

Research output: Contribution to journalScientific review

View graph of relations

Authors

  • Grainne M. O'Regan
  • Aileen Sandilands
  • W. H. Irwin McLean
  • Alan D. Irvine

Research units

Info

Original languageEnglish
Pages689-693
Number of pages5
JournalJournal of Allergy and Clinical Immunology
Journal publication dateOct 2008
Journal number4
Volume122
DOIs
StatePublished

Abstract

The recent identification of loss-of-function mutations in the structural protein filaggrin as a widely replicated major risk factor for eczema sheds new light on disease mechanisms in eczema, a disease that had heretofore largely been considered to have a primarily immunologic etiopathogenesis. The filaggrin gene (FLG) mutation findings are consistent with a recently proposed unifying hypothesis that offers a mechanistic understanding of eczema pathogenesis synthesizing a heritable epithelial barrier defect and resultant diminished epidermal defense mechanisms to allergens and microbes, followed by polarized T(H)2 lymphocyte responses with resultant chronic inflammation, including autoimmune mechanisms. Although compelling evidence from genetic studies on FLG implicates perturbed barrier function as a key player in the pathogenesis of eczema in many patients, much is still unknown about the sequence of biologic, physicochemical, and aberrant regulatory events that constitute the transition from an inherited barrier defect to clinical manifestations of inflammatory eczematous lesions and susceptibility to related atopic disorders. The exact contribution of FLG to the wider atopic story, factors modifying FLG expression, and the role of other barrier proteins remain to be delineated. In this review we highlight recent advances in our understanding of the FLG genetics in the cause of eczema and related complex diseases.

Documents

Library & Learning Centre

Contact | Accessibility | Policy